FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2781574428> ?p ?o ?g. }

• W2781574428 endingPage "73" @default.
• W2781574428 startingPage "68" @default.
• W2781574428 abstract "No AccessJournal of UrologyAdult Urology1 Jul 2018Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma Ross S. Liao, Mohit Gupta, Zeyad R. Schwen, Hiten D. Patel, Max Kates, Michael H. Johnson, Noah M. Hahn, David McConkey, Trinity J. Bivalacqua, and Phillip M. Pierorazio Ross S. LiaoRoss S. Liao Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Mohit GuptaMohit Gupta Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Zeyad R. SchwenZeyad R. Schwen Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Hiten D. PatelHiten D. Patel Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Max KatesMax Kates Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Michael H. JohnsonMichael H. Johnson Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Noah M. HahnNoah M. Hahn Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , David McConkeyDavid McConkey Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Trinity J. BivalacquaTrinity J. Bivalacqua Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , and Phillip M. PierorazioPhillip M. Pierorazio Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.12.054AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: High risk upper tract urothelial carcinoma has been associated with poor survival outcomes. Limited retrospective data support neoadjuvant chemotherapy prior to radical nephroureterectomy. To validate prior findings we evaluated differences in the pathological stage distribution in patients with high risk upper tract urothelial carcinoma based on the administration of neoadjuvant chemotherapy before radical nephroureterectomy. Materials and Methods: We retrospectively analyzed the records of 240 patients with upper tract urothelial carcinoma at The Johns Hopkins Hospital from 2003 to 2017. Patients with biopsy proven high grade disease and a visible lesion on cross-sectional imaging were offered neoadjuvant chemotherapy prior to radical nephroureterectomy. A control group of a time matched cohort of patients with biopsy proven high grade disease underwent extirpative surgery alone. The chi-square and Fisher exact tests were used to evaluate clinical and pathological variables between the cohorts. Results: There were 32 patients in the study group and 208 in the control group. Significantly lower pathological stage was noted in the study group than in the control group (p <0.001). Significantly fewer patients with pT2 disease or higher were treated with neoadjuvant chemotherapy (37.5% vs 59.6%, p = 0.02). There was a 46.5% reduction in the prevalence of pT3 disease or higher in study group patients without clinically node positive or low volume metastatic disease (25.9% vs 48.4%, p = 0.04). A 9.4% complete remission rate was observed in patients who underwent neoadjuvant chemotherapy. Conclusions: Patients with high risk upper tract urothelial carcinoma treated with neoadjuvant chemotherapy were noted to have a lower pathological stage distribution than patients treated with radical nephroureterectomy alone. References 1 : Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol2003; 47: 155. Google Scholar 2 : Ureteroscopic management of upper tract transitional cell carcinoma. Urol Clin North Am2004; 31: 115. Google Scholar 3 : Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology2006; 67: 1181. Google Scholar 4 : Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol1997; 157: 33. Link, Google Scholar 5 : Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. BJU Int2006; 98: 1176. Google Scholar 6 : Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer1999; 35: 738. Google Scholar 7 : Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology1998; 52: 594. Crossref, Medline, Google Scholar 8 : Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol2007; 51: 1281. Google Scholar 9 : Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol2001; 19: 4005. Google Scholar 10 : Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol2005; 48: 202. Google Scholar 11 : Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer2010; 116: 3127. Google Scholar 12 : Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer2014; 120: 1794. Google Scholar 13 : Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology2010; 76: 895. Google Scholar 14 : A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology2010; 75: 315. Google Scholar 15 : Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol2012; 62: 100. Google Scholar 16 : Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol2012; 30: 266. Google Scholar 17 : Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003; 349: 859. Google Scholar 18 : Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res2006; 12: 139. Google Scholar 19 : Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int2011; 108: 1286. Google Scholar 20 : Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer2009; 115: 1224. Google Scholar 21 : Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology2007; 70: 662. Google Scholar 22 : Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer2010; 116: 2967. Google Scholar 23 : Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol2010; 58: 581. Google Scholar 24 : Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open2017; 1: e000126. Google Scholar © 2018 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byFoerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku J, Muilwijk T, Kassouf W, Matin S, Spiess P, Pierorazio P, Hendricksen K, Shariat S, Clinton T, Broutian T, Bandini M, Monteiro L, Liao R, Moschini M, Bivalacqua T, Krabbe L, Nasu Y, Egawa S, Joniau S, John H, van der Heijden M, Glybochko P, Fajkovic H, Singla N and Necchi A (2020) Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial CarcinomaJournal of Urology, VOL. 203, NO. 6, (1101-1108), Online publication date: 1-Jun-2020.Smith J (2018) This Month in Adult UrologyJournal of Urology, VOL. 200, NO. 1, (1-2), Online publication date: 1-Jul-2018. Volume 200Issue 1July 2018Page: 68-73Supplementary Materials Advertisement Copyright & Permissions© 2018 by American Urological Association Education and Research, Inc.Keywordsneoadjuvant therapytransitional cellchemotherapycarcinomaureteral neoplasmskidney neoplasmsMetricsAuthor Information Ross S. Liao Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Mohit Gupta Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Zeyad R. Schwen Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Hiten D. Patel Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Max Kates Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Michael H. Johnson Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Noah M. Hahn Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author David McConkey Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Trinity J. Bivalacqua Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Phillip M. Pierorazio Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2781574428 created "2018-01-12" @default.
• W2781574428 creator A5001308517 @default.
• W2781574428 creator A5002892743 @default.
• W2781574428 creator A5011625882 @default.
• W2781574428 creator A5018425564 @default.
• W2781574428 creator A5029009031 @default.
• W2781574428 creator A5049688133 @default.
• W2781574428 creator A5059536506 @default.
• W2781574428 creator A5063510741 @default.
• W2781574428 creator A5070240832 @default.
• W2781574428 creator A5077350606 @default.
• W2781574428 date "2018-07-01" @default.
• W2781574428 modified "2023-09-28" @default.
• W2781574428 title "Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma" @default.
• W2781574428 cites W1527366898 @default.
• W2781574428 cites W1942258069 @default.
• W2781574428 cites W1972649200 @default.
• W2781574428 cites W1975918912 @default.
• W2781574428 cites W1980525903 @default.
• W2781574428 cites W1987008857 @default.
• W2781574428 cites W1990070131 @default.
• W2781574428 cites W2000415625 @default.
• W2781574428 cites W2006030842 @default.
• W2781574428 cites W2010513628 @default.
• W2781574428 cites W2032471331 @default.
• W2781574428 cites W2048932561 @default.
• W2781574428 cites W2051346092 @default.
• W2781574428 cites W2068972734 @default.
• W2781574428 cites W2074306143 @default.
• W2781574428 cites W2077825533 @default.
• W2781574428 cites W2085833972 @default.
• W2781574428 cites W2088929974 @default.
• W2781574428 cites W2121543824 @default.
• W2781574428 cites W2132907440 @default.
• W2781574428 cites W2151508785 @default.
• W2781574428 cites W2166453367 @default.
• W2781574428 cites W2470654889 @default.
• W2781574428 cites W2582834090 @default.
• W2781574428 cites W4376546343 @default.
• W2781574428 doi "https://doi.org/10.1016/j.juro.2017.12.054" @default.
• W2781574428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29307680" @default.
• W2781574428 hasPublicationYear "2018" @default.
• W2781574428 type Work @default.
• W2781574428 sameAs 2781574428 @default.
• W2781574428 citedByCount "40" @default.
• W2781574428 countsByYear W27815744282018 @default.
• W2781574428 countsByYear W27815744282019 @default.
• W2781574428 countsByYear W27815744282020 @default.
• W2781574428 countsByYear W27815744282021 @default.
• W2781574428 countsByYear W27815744282022 @default.
• W2781574428 countsByYear W27815744282023 @default.
• W2781574428 crossrefType "journal-article" @default.
• W2781574428 hasAuthorship W2781574428A5001308517 @default.
• W2781574428 hasAuthorship W2781574428A5002892743 @default.
• W2781574428 hasAuthorship W2781574428A5011625882 @default.
• W2781574428 hasAuthorship W2781574428A5018425564 @default.
• W2781574428 hasAuthorship W2781574428A5029009031 @default.
• W2781574428 hasAuthorship W2781574428A5049688133 @default.
• W2781574428 hasAuthorship W2781574428A5059536506 @default.
• W2781574428 hasAuthorship W2781574428A5063510741 @default.
• W2781574428 hasAuthorship W2781574428A5070240832 @default.
• W2781574428 hasAuthorship W2781574428A5077350606 @default.
• W2781574428 hasConcept C121608353 @default.
• W2781574428 hasConcept C126322002 @default.
• W2781574428 hasConcept C126894567 @default.
• W2781574428 hasConcept C143998085 @default.
• W2781574428 hasConcept C146357865 @default.
• W2781574428 hasConcept C151730666 @default.
• W2781574428 hasConcept C207886595 @default.
• W2781574428 hasConcept C2776694085 @default.
• W2781574428 hasConcept C2780352672 @default.
• W2781574428 hasConcept C3019882237 @default.
• W2781574428 hasConcept C3020745361 @default.
• W2781574428 hasConcept C71924100 @default.
• W2781574428 hasConcept C86803240 @default.
• W2781574428 hasConceptScore W2781574428C121608353 @default.
• W2781574428 hasConceptScore W2781574428C126322002 @default.
• W2781574428 hasConceptScore W2781574428C126894567 @default.
• W2781574428 hasConceptScore W2781574428C143998085 @default.
• W2781574428 hasConceptScore W2781574428C146357865 @default.
• W2781574428 hasConceptScore W2781574428C151730666 @default.
• W2781574428 hasConceptScore W2781574428C207886595 @default.
• W2781574428 hasConceptScore W2781574428C2776694085 @default.
• W2781574428 hasConceptScore W2781574428C2780352672 @default.
• W2781574428 hasConceptScore W2781574428C3019882237 @default.
• W2781574428 hasConceptScore W2781574428C3020745361 @default.
• W2781574428 hasConceptScore W2781574428C71924100 @default.
• W2781574428 hasConceptScore W2781574428C86803240 @default.
• W2781574428 hasIssue "1" @default.
• W2781574428 hasLocation W27815744281 @default.
• W2781574428 hasLocation W27815744282 @default.
• W2781574428 hasOpenAccess W2781574428 @default.
• W2781574428 hasPrimaryLocation W27815744281 @default.
• W2781574428 hasRelatedWork W1964795883 @default.
• W2781574428 hasRelatedWork W1987468340 @default.
• W2781574428 hasRelatedWork W2053546346 @default.
• W2781574428 hasRelatedWork W2312507597 @default.

• next